Abstract: Transform growth factor-β1 (TGF-β1) is an extremely powerful protein to induce the chondrogenesis of mesenchymal stem cells (MSCs) both in vitro and in vivo. However, due to the short-life of TGF-β1, the direct application of TGF-β1 may deteriorate its bioactivity and thereby the repair effect. In this study, uniform sulfated chitosan microspheres (SCMs) with a mean diameter of ∼ 2 μm were fabricated by membrane emulsification as a carrier for TGF-β1. The in vitro release study showed that TGF-β1 could be sustainedly released from the microspheres up to 16 days. Under the protection of SCMs, about 13 % TGF-β1 was preserved even after stored for 14 days. The microspheres cytotoxicity was evaluated by coculture of MSCs with different concentrations SCMs and no obvious deterioration of cell viability was observed when the concentration of SCMs is lower than 2 μg/1.0 × 10 4 cells. In comparison with the blank group, the addition of TGF-β1 either in free state or loaded in SCMs inhibited the proliferation trend of MSCs. Quantitative analysis of GAGs production and genes expression of COL II and aggrecan by qRT-PCR revealed that enhanced bioactivity of TGF-β1 was obtained in the group of TGF-β1/SCMs, indicating that SCMs could be functioned as a promising carrier of TGF-β1 for the in vitro chondrogenesis of MSCs.
Introduction
In cartilage restoration study, mesenchymal stem cells (MSCs) have attracted many attentions due to the potentials of differentiating into different cell lineages such as chondrocytes and osteoblasts [1] [2] [3] . Many striking results have been acquired to demonstrate the promising application of MSCs in cartilage repair [4, 5] . The key issue of its application in cartilage restoration is to control MSCs differentiation into chon-drocytes, secretion of corresponding extracellular matrix and maintainence of proper cell phenotype [6] [7] [8] . However, the guided differentiation of MSCs depends on the specific biological cues and stimuli such as exogenous growth factors [9, 10] , gene [11] , modulus [12] , cell seeding density and properties of surface of materials [13] . Among these, a variety of growth factors such as the TGF-β superfamily and the transcription factors including SOX5, SOX6, and SOX9 play a great role in the induced differentiation of MSCs [14, 15] . Some previous studies proved that TGF-β1 is extremely powerful to induce the chondrogenesis of MSCs both in vitro and in vivo and has been applied widely in the studies of cartilage restoration [16, 17] .
However, due to the short-life of TGF-β1, the direct application of TGF-β1 may deteriorate its bioactivity [18] . In addition, high dose of TGF-β1 for local implantation may be associated with potential side effects, which may activate inflammatory reaction and result in the formation of fibrosis and osteophyte [19, 20] . It necessitates the development of a releasing system to provide TGF-β1 in a controlled manner to stimulate the differentiations of MSCs. Carrier, a promising release system for growth factors, have been used widely to control the release of TGF-β1 in defined rate. Until now, many types of carriers such as PLGA microspheres by emulsion protocol, multilayered microspheres by layer by layer process, and nanoparticles by coprecipitation method have been reported [21] [22] [23] [24] . Among them, microspheres with good reproducibility, great bioavailability and repeatable release behavior have attracted many attentions [25] .
As a kind of materials for anticoagulation, heparin was also reported to possess the property of protecting the bioactivity of growth factors, contributing to the specific interaction between heparin and growth factors [26] [27] [28] [29] [30] . Heparin/TGF-β1 nanoparticles were prepared by coprecipitation to control the release of TGF-β1 with preserved bioactivity [31] . Heparined chitosan/poly(γ-glutamic acid) nanoparticles were prepared for retaining of basic fibroblast growth factor (bFGF) mitogenic activity [32] . Modifications of PLGA nanoparticles by heparinization were reported to control release and improve the bioactivity vascular endothelial growth factor (VEGF) [33] . However, the application of heparin in the protection of growth factors was hampered because of the risk of hemorrhage and osteoporosis in long term [34] . Moreover, due to the low molecular weight of heparin, it is hard to prepare microspheres directly. To overcome the above shortcomings, sulfated chitosan, which has the similar effect on protecting bioactivity of growth factors, has been considered as a promising alternative [35] . Moreover, sulfated chitosan has much higher molecular weight than native heparin to facilitate the fabrication of microspheres.
In this study, by combining the advantages of sulfated chitosan in bioactivity protection and microspheres in controlled release, sulfated chitosan microspheres (SCMs) was prepared by membrane emulsification as a promising carrier to control the release of TGF-β1 with enhanced bioactivity. The morphology, surface properties of SCMs, as well as the releasing behaviors of TGF-β1 from this carrier were characterized. By in vitro cell culture, the enhanced property of TGF-β1 for the in vitro chondrogenesis of MSCs was evaluated.
Materials and methods

Materials
Chitosan (deacetylation degree 85 %, Mη = 2.5 × 10 4 ) was a product from Haidebei Bioengineering Co. Ltd. (Qingdao, China). Recombinant human TGF-β1 was purchased from Peprotech (New Jersey, USA). Dichloroacetic acid (DCAA), N,N-dimethylformamide (DMF), sodium borohydride, glutaraldehyde (GA), isopropyl alcohol, and petroleum ether were purchased from Sinopharm Chemical Reagent Co. Ltd. (Shanghai, China). All other chemicals were of regent grade and were used as received.
3,6-O-sulfated chitosan was prepared according to Ronge Xing's methods with modification [36] . Briefly, sulfating reagent was prepared by adding 5 mL of HClSO 3 dropwise with stirring to 20 mL DMF which was previously cooled at 0∼4 °C. 25 mL sulfating reagent were added to 60 mL chitosan solution containing 2 mL DCAA with swirling. Then the reaction was run at 65 °C for 2 h, and then washed with 95 % ethanol and water, respectively. The solution was dialyzed against deionized water, and then lyophilized to get 3,6-O-sulfated chitosan. The number average molecular weight and the sulfur content of the obtained sulfated chitosan was 2.5 × 10 4 and 20.7 %, respectively.
Preparation of SCMs
SCMs were fabricated by membrane emulsification with some modifications [25] . Briefly, sulfated chitosan dissolved in water with the concentration of 1.5 %. A definite volume of sulfated chitosan solution was pressed though the glass membrane with uniform pore size of 1.9 μm into oil phase (liquid paraffin and Span-80 in a volume ratio of 24:1) under nitrogen pressure (5∼15 kPa). The volume ratio of aqueous solution and liquid paraffin is 1:75. At the end of emulsification, the emulsion was cross-linked by glutaraldehyde with same volume of sulfated chitosan solution at 37 °C for 4 h. After washed three times with petroleum ether, isopropyl alcohol and Milli-Q water respectively, sodium borohydride was added to react with the remaining of aldehyde group in consideration of toxicity of glutaraldehyde. SCMs were collected by lyophilization and stored at 4 °C for further experiments.
Loading of TGF-β1
TGF-β1 was loaded by immersing 50 μg sterilized SCMs into 150 μL 0.1 % bull serum albumin/phosphatebuffered saline solution (0.1 % BSA/PBS, pH = 7.2) containing 100 ng TGF-β1 at room temperature for 30 min with shaking. Then the mixture was incubated at room temperature for 30 min and remove supernatant by centrifugation to obtain TGF-β1/SCMs. To determine the loading efficiency of TGF-β1, TGF-β1 concentration of supernatant was assayed by enzyme-linked immunosorbent assay kit (ELISA, eBioscience, San Diego, USA).
Characterization of SCMs
The morphology of SCMs before and after adsorption of TGF-β1 was measured by scanning electron microscope (SEM, Hitachi S-4800, Tokyo, Japan). The mean diameters of SCMs and TGF-β1/SCMs were determined using a dynamic lighting scattering (DLS) method by a Particle Size Analyzer (Brookhaven, USA) at 25 °C and a fixed light angle of 90°. The ζ potential of the microspheres was tested using a ζ Potential Analyzer (DelsaTM, Beckman Coulter, Brea, USA).
TGF-1 release study
TGF-β1/SCMs were incubated with 120 μL 0.1 % BSA/PBS in capped tube under static condition. At each time point, sample was centrifuged for 6 min at 8000 rpm to collect the supernatant. Then 120 μL fresh 0.1 % BSA/ PBS was added to each sample, which was incubated until the next time point. The collected supernatant was stored at -80 °C until further analysis. ELISA was used to determine the concentration of the released TGF-β1.There samples were analyzed for each time point.
Bioactivity of TGF-β1 with the storage time
TGF-β1/SCMs were incubated with 120 μL 0.1 % BSA/PBS in capped tube under static condition. At each time point, the sample was centrifuged for 6 min at 8000 rpm. 120 μL fresh 0.1 % BSA/PBS was added and then incubated for 4 h with shaking. After incubation, the sample was centrifuged for 6 min at 8000 rpm again, following by collection of supernatant. The collected supernatant was stored at -80 °C for further analysis. The concentration of the released TGF-β1 was measured by ELISA. There samples were analyzed for each time point.
Cell culture
MSCs were isolated from bone marrow aspirate of New Zealand rabbits as describe previously [5] . Briefly, appropriate volume rabbit bone marrow was aspirated into a 10 mL sterile syringe containing 5000 U heparin, and then diluted with Dulbecco's modified Eagle's medium (DMEM, GIBCO, Wu han, China). The mixture was centrifuged two times with a speed of 2000 rpm for 20 min. The precipitate cell pellet was cultured in low-glucose DMEM containing 10 % bovine serum (GIBCO, Wu han, China), 100 U/mL penicillin and 100 μg/ mL streptomycin. After incubation at 37 °C under 5 % CO 2 for 5 days, non-adherent cells were removed by washing twice with the basal medium. Medium was changed every two days until reaching 90 % confluence. MSCs were retrieved by treatment with 0.25 % trypsin and employed at passages 2 or 3.
Cytotoxicity of SCMs
MSCs were seeded in 96-well plate at a destiny of 
Cell proliferation
Transwells model was used to evaluate cell proliferation behaviors [37] . MSCs were seeded in the bottom layer of 12-well plate at a destiny of 1.5 × 10 4 cells/well and then incubated at 37 °C under 5 % CO 2 for 1 day. After one day's incubation, 2 mL culture medium containing TGF-β1/SCMs (2 μg/ml SCMs, 5 ng/ml TGF-β1) were added. The culture mediums containing the same concentration of SCMs or TGF-β1 respectively were chosen as the controls. The culture medium was changed twice per week. At each time point, the cell plate was washed twice with PBS and stored at -20 °C for further analysis. DNA content was performed by PicoGreen assay (Molecular Probes, Eugene, USA) according to the instructions of the manufacturer. Samples were run in quadruplicate for each experiment.
Quantitative analysis of GAG secretion
The quantity of the secreted GAGs was assayed by Alcian blue dye assay. At each point, 200 μL papain solutions was added to the samples for digestion, and then the mixture was incubated with 200 μL of 1.4 mg/mL Alcian blue dye for 10 min. The adsorption of the mixture at 490 nm was measured by a spectrophotometer, with chondroitin sulfate C (Sigma, Santa Clara, USA) as a standard.
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)
qRT-PCR was used to detect the expression of chondrogenesis-related genes, i.e., type II collagen and aggrecan. The samples were prepared as described in section of cell proliferation. At day 14, the cell layer was detached from each well using 2.5 % trypsine. Total RNAs were extracted from each sample by RNeasy Mini Kit (Qiagen, Duesseldorf, Germany), and 1 μg of total RNAs was reverse-transcribed to complementary DNA (cDNA) with Omniscript RT Kit (Qiagen). Glyceraldehydes-3-phosphate dehydrogenase (GAPDH) was chosen as the internal control gene. Table S1 list the primer sequence of analyzed genes and GAPDH. An ABI 7300 realtime PCR system (Applied Biosystems, Eugene, USA) with SYBR Green PCR master mix (Applied Biosystems, Eugene, USA) was used to carry out qRT-PCR and the conditions was 15 s at 90 °C, 60 s at 60 °C. Fluorescence intensity was recorded for 40 cycles [11] . The qRT-PCR assays were run in triplicate for each experiment.
Statistical analysis
Data are expressed as mean ± SD. Differences between experimental groups are assessed by ANOVA. p-values < 0.05 were considered statistically significant difference.
Results
Characterizations of SCMs
To investigate the effects of TGF-β1 loading on the morphology and size of SCMs, SEM images of SCMs before and after TGF-β1 loading were displayed in Fig. 1 . It is shown that SCMs had a uniform size of 1.9 ± 0.04 μm and smooth morphology without obvious cracks or wrinkles (Fig. 1a) . Figure 1b displayed the size distribution of SCMs and TGF-β1/SCMs in water, which exhibited a unimodal and narrow peak at 5.4 μm and 5.7 μm, respectively (Fig. 1b) . There were no significant differences in size distribution between SCMs and TGF-β1/ SCMs. The size difference of SCMs at dry state and in solution could be contributed to microspheres swell after uptaken a large amount of water. As shown in Fig. 1c , after loading of TGF-β1, the morphology and size of TGF-β1/SCMs did not show significant difference in comparison with SCMs. ζ-potentials of the microspheres before and after TGF-β1 loading were compared in Fig. 1d . Before loading, SCMs had a ζ-potential of -25 mV because of the negative charge of sulfated chitosan. Due to the positive charge of TGF-β1, the ζ-potential of TGF-β1/SCMs significantly increased to -4 mV, indicating the successful loading of TGF-β1 into the microspheres (Fig. 1d) . 
TGF-β1 release behavior
The effects of TGF-β1 released from a carrier on MSCs differentiation are dependent on many factors, among which its release behavior is considered as the crucial one [9] . A cumulative release profile was plotted to evaluate the release behavior of TGF-β1 from TGF-β1/SCMs (Fig. 2a) . It was shown that TGF-β1 was released in a controlled manner, except for the slight burst release in the initial stage. The profile showed that the release speed was much higher before day 5, while 28 % of TGF-β1 were released from TGF-β1/SCMs. From day 5 to day 16, only a small quantity of TGF-β1 was gradually released from SCMs. Correlated to the total loading amount, 35 % of TGF-β1 was released up to 16 days.
Bioactivity of TGF-β1 with the storage time
To evaluate the ability of SCMs to protect TGF-β1 bioactivity during the long-term storage, the amount of the freshly released TGF-β1 with the storage time was measured (Fig. 2b) . After stored for 1 day, 24 % TGF-β1 with preserved bioactivity were released from SCMs after 4 h incubation. At the storage time of day 3 and day 5, no significant difference was observed in the released amount of the bioactive TGF-β1 compared to that of day 1. With the increase of the storage time, the amount of released TGF-β1 decreased gradually. 13 % of TGF-β1 could be still detected after stored in SCMs for 14 days. It indicates that the bioactivity of TGF-β1 loaded in SCMs could be preserved for much longer than that in medium, which could be attributed to the synergetic effect of microspheres and sulfated chitosan.
Cytotoxicity of SCMs
To determine the appropriate feeding concentration of SCMs in the following differentiation studies, the viabilities of MSCs cocultured with the different concentrations of SCMs were measured by MTT assay (Fig. 3) . At day 1 and day 2, no obvious dependence of cell viabilities on the feeding concentration of SCMs was found. With increase of culture time, the cell viability gradually increased for all the samples with regardless of the concentration of SCMs. From day 3, the effects of the SCMs concentration on the cells viability became obvious. It is shown that with the increase of the feeding concentration of SCMs, the cells viability gradually decreased. The lowest value of cell viability was obtained when 10 μg/1.0 × 10 4 cells SCMs was added. However, no obvious deterioration of cell viability was observed when the concentration of SCMs is lower than 2 μg/1.0 × 10 4 cells, which was considered as the upper limit of the safe concentration in the following studies. 
Cell proliferation
In order to avoid the impact of interaction between SCMs and cells, transwells model was used to determine the efficiency of released TGF-β1 on cells behaviors. Firstly, the proliferation behaviors of MSCs alone (Blank) or cocultured with SCMs, TGF-β1 and TGF-β1/SCMs were assayed respectively by counting cells number with culture time (Fig. 4) . For the groups of Blank and SCMs, the number of cells increased gradually with the culture time during the 14-days cultivation. For the groups of TGF-β1 and TGF-β1/SCMs, a significant increase of cells number could be found from day 3 to day 7, but no further increase at day 14. At all the time point, the TGF-β1 released from TGF-β1/SCMs showed almost the same effect on the proliferation of MSCs cocultured with free TGF-β1. At day 14, the number of MSCs in Blank group showed the highest value in comparison to the groups of TGF-β1 and TGF-β1/SCMs.
GAGs secretion
As one of the main components of cartilage ECM, GAGs is frequently selected as criteria to judge the degree of MSCs differentiation into chondrocytes [31] . As shown in Fig. 5 , the amounts of GAGs secreted by MSCs cultured in different conditions were measured. For all the groups, the amounts of GAGs increased gradually with the prolongation of culture time. At day 14, the highest level of GAGs production (up to 50 mg/mL GAGs in the medium) was obtained in the group of TGF-β1/SCMs, the value of which is almost twice of that of blank group. Additionally, TGF-β1/SCMs had a significant impact on the production of GAGs in comparison to free TGF-β1 during culture period. Interestingly, the addition of TGF-β1 in free model had no obvious effect on the GAGs secretion compared to the groups of blank and SCMs. The similar results were also obtained from the results of GAGs staining by Alcian blue (data not shown). The promoting effect of TGF-β1/SCMs on GAGs secretion proved that, the chondrogenic differentiation of MSCs was preceded more deeply under the stimulating of released TGF-β1, indicating the protection of SCMs.
Expression of chondrogenesis-related genes
The expression of cartilage-related proteins such as COL II and aggrecan is indispensable to realize the restoration of damaged cartilage [5] . To assay the chondrogenesis of MSCs cocultured at different conditions, the expression of chondrogenesis-related genes such as collagen II and aggrecan was determined by qRT-PCR. As shown in Fig. 6 , after 14-days cultivation, both collagen II and aggrecan were highly expressed at the groups with the additional of TGF-β1 compared to the others (Fig. 6 ). As shown in Fig. 6a , the medium containing TGF-β1/SCMs had a higher level of collagen II expression in comparison to that containing free TGF-β1. In the TGF-β1 free groups, the presence of SCMs had no obvious effect on stimulating the expression of collagen II in comparison to the blank group. Similar to the results of collagen II, aggrecan expression was also upregulated by the presence of TGF-β1/SCMs (Fig. 6b) .
Discussion
As we mentioned before a key issue to induced chondrogenic differentiation of MSCs is the bioactivity of TGF-β1. In this paper, the effects of TGF-β1/SCMs on bioactivity of TGF-β1 for in vitro chondrogenesis of MSCs were investigated. SCMs with narrow size distribution were prepared by membrane emulsification, and then TGF-β1/SCMs were fabricated after adsorption of TGF-β1. Compare to traditional method to prepare microspheres loading growth factors, our method were to separate the SCMs preparation and TGF-β1 loading. It could diminish the denaturation degree of growth factors, which mostly occur during carrier preparation step because of the contaction of TGF-β1 and organic solution.
One characteristic of SCMs and TGF-β1/SCMs were controllable size (Fig. 1a, c) and narrow size distribution (Fig. 1b) , which was regarded as one of the key parameters to determine the properties of a promising carrier. Some studies showed that uniform carriers would perform well in reproducibility and repeatable release behavior for their applications in drug delivery system [25] . Expansion was the other characteristic of our SCMs. The size difference of SCMs at dry state and in solution could be contributed to microspheres swell after uptaken a large amount of water and the expansion ratio of TGF-β1/SCMs was about 400 % in the presence of TGF-β1 solution.
When SCMs were incubated with 100 ng/mL TGF-β1 solution, most of free TGF-β1 in solution was successfully absorbed into the microspheres, resulting from significant changeable ζ-potentials of SCMs (Fig. 1d) . Meanwhile, the loading efficiency of higher than 95 % of TGF-β1 could be contributed to both the high swollen ratio of SCMs and the electrostatic interaction between sulfated chitosan and TGF-β1. Moreover, surface properties of microspheres play crucial role in determining the interaction between carriers and cells [38, 39] and also influence the cytotoxicity of cell [40] . From our result, there was no obvious deterioration of cell viability when 10 μg/1.0 × 10 4 cells SCMs were added (Fig. 3 ). Sulfated chitosan have been shown to interact with BMP due to the specific interaction between sulfate groups of sulfated chitosan and lysine or arginine cations in proteins [41] . Several studies have suggested that the potency of sulfated chitosan to enhance the bioactivity of BMP was much higher than heparin due to the specific interaction [42] . The cellulose sulfates possess a stimulatory effect on osteogenic activity of BMP resulting from the sulfate groups [43] . Our previous study suggested that sulfated chitosan solution had protective ability of bFGF [35] . A gentle release of protein might be achieved by the specific interaction and physical absorption between sulfated chitosan and protein. It was found in this study that TGF-β1 could be released in a relatively gentle way from TGF-β1/SCMs in the whole period (Fig. 2a) and the bioactivity of TGF-β1 loaded in SCMs could be preserved for long time (Fig. 2b) . The relatively gentle release behaviors was attributed to the specific interaction between sulfated chitosan and TGF-β1. Meanwhile, the slight burst release in the initial stage may be attributed to the proteins adsorbed on the microspheres surface. The amount of TGF-β1 seemed too low compared to the total loading amount due to the denaturation of the released TGF-β1 in medium.
The effect of the TGF-β1/SCMs on chondrogenic differentiation of MSCs was evaluated by cell proliferation, GAGs secretion and gene expression. It is well known that the proliferation and differentiation are contradictory, which can not progress at same time. For cells showing a proliferating trend, its potential for differentiation will be depressed [44] [45] [46] . From our result, MSCs under the treatment of TGF-β1/SCMs or free TGF-β1 had a stronger trend to differentiate than to proliferate (Fig. 4) . TGF-β1 and TGF-β1/SCMs had same effect on proliferation of MSCs.
Cartilage-specific ECM components such as GAGs, aggrecan and collagen type II were measured as a means to examine the chondrogenic differentiation of MSCs. From our results, compared to free TGF-β1, TGF-β1/SCMs had much more simulative effect on the secretion of GAGs (Fig. 5) and expression of collagen type II (Fig. 6a) and aggrecan (Fig. 6b) . As we all known that TGF-β1 stimulation is essential for chondrogenic differentiation of MSCs and ECM deposition especially in the late stage. The up-regulation of COL II and aggrecan gene expression could be attributed to the long-term existence of bioactive TGF-β1 released from TGF-β1/SCMs in comparison to free TGF-β1 exposed to medium. The release behaviors influence the process of differentiation of MSCs, and numerous studies shown that several growth factors were need in concentration-dependent pattern to induce cells differentiation and trigger the would healing and tissue regeneration [9, [47] [48] [49] [50] . Therefore, the long-term release behavior of TGF-β1 from TGF-β1/SCMs plays vital roles in chondrogenic differentiation of MSCs. Additionally, it has been reported that polysulfate group in heparin may have positive effects on enhancing the differentiation of MSCs and chondrocyte [51, 52] . It could be the reason to explain the slight acceleration of COL II and aggrecan expression in SCMs group. Some studies suggested that heparinized nanoparticles loaded with TGF-β3 resulted in significant expression of COL II and aggrecan by MSCs in hydrogels, and their TGF-β3 release from hydrogels was slower than free state TGF-β3 [31] .
Regarding to the TGF-β1 with high cost and easily inactivation caused by alteration of microenvironment, our study has successfully established a novel carrier for protective-bioactivity of TGF-β1. For cultivation of MSCs in vitro, chondrogenic differentiation was evaluated to confirm the protective-ability of sulfated chitosan microspheres. On the other hand, further research of these specific interactions between sulfated chitosan and TGF-β1 will hasten the application in cartilage regeneration.
Conclusion
In summary, as a carrier for TGF-β1, sulfated chitosan microspheres (SCMs) were fabricated by membrane emulsification. No obvious change could be found on the morphology of microspheres before and after TGF-β1 loading, the mean size of which was about 2 μm with a narrow distribution. However, compared to the negative charge surface of SCMs, the loading of TGF-β1 increased the ζ-potentials of TGF-β1/SCMs because of the positive charge nature of TGF-β1. A long-term releasing profile of TGF-β1 was obtained in the in vitro release study, which was gradually released from TGF-β1/SCMs till to 16 days. Under the protection of SCMs, the bioactivity of TGF-β1 could be preserved even after stored for 14 days. No obvious cytotoxicity of SCMs was detected in the coculture test with MSCs. By the stimulation of TGF-β1 release from SCMs, more secreted GAGs and relative higher genes expression of COL II and aggrecan were obtained in comparison to the blank, SCMs and TGF-β1 groups, indicating that the bioactivity of TGF-β1 could be enhanced under the protection of SCMs. All these results indicated that SCMs could be functioned as a promising carrier of TGF-β1 for the in vitro chondrogenesis of MSCs and show the potentials for the in vivo application for cartilage restoration.
